Gravity Analytica

PureTech to Present at Two Upcoming Investor Conferences

PRTC 10.30.2024

SERA-AI Powered Highlights

Date of Upcoming Event:2024-11-13

Name of Upcoming Event:UBS Global Healthcare Conference

Date of Upcoming Event:2024-11-19

Name of Upcoming Event:Jefferies London Healthcare Conference

Full Press Release SEC Filings Our PRTC Tweets

About Gravity Analytica

Recent Filings

PDF Version

RNS Number : 1291K

PureTech Health PLC

30 October 2024

30 October 2024

PureTech Health plc

PureTechto Present at Two Upcoming Investor Conferences

PureTech Health plc(Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that members of the management team will participate in two upcoming investor conferences. Webcasts of the presentations will be available athttps://investors.puretechhealth.com.

UBS Global Healthcare Conference

Presenters:Bharatt Chowrira, Ph.D., J.D., Chief Executive Officer, andEric Elenko, Ph.D., Co-founder and President

Date:Wednesday, November 13, 2024

Time:8:45 a.m. PST

Jefferies London Healthcare Conference

Presenters:Bharatt Chowrira, Ph.D., J.D., Chief Executive Officer, andEric Elenko, Ph.D., Co-founder and President

Date:Tuesday, November 19, 2024

Time:2:30 p.m. GMT

AboutPureTech Health

PureTechis a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities.PureTech'sR&D engine has resulted in the development of 29 therapeutics and therapeutic candidates, including three that have been approved by theU.S. Food and Drug Administration. A number of these programs are being advanced byPureTechor its Founded Entities in various indications and stages of clinical development, including registration enabling studies. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by thePureTechteam through key validation points.

For more information, visitwww.puretechhealth.comor connect with us on X (formerly Twitter) @puretechh.

Cautionary Note Regarding Forward-Looking Statements

This press release contains statements that are or may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation those related to our future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks, uncertainties and other important factors described under the caption "Risk Factors" in our Annual Report on Form 20-F for the year endedDecember 31, 2023, filed with theSECand in our other regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, we disclaim any obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:

PureTech

Public Relations

publicrelations@puretechhealth.com

InvestorRelations

IR@puretechhealth.com

UK/EU Media

Ben Atwell,Rob Winder

+44 (0) 20 3727 1000

puretech@fticonsulting.com

US Media

Justin Chen

+1-609-578-7230

jchen@tenbridgecommunications.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of theLondon Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contactrns@lseg.comor visitwww.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and theLondon Stock Exchangeuse the personal data you provide us, please see ourPrivacy Policy.

END

NRAPPGPGUUPCPUB

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com